Celecoxib

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

47 publications

Celecoxib Chemical Structure

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 420 In stock
USD 70 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Celecoxib has been cited by 47 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M{KyeGZ2dmO2aX;uJGF{e2G7 Ml:2NE4yNTNyIN88US=> MUm0PEBp Ml;JbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> NHXRT|QzPjVzM{G3Ni=>
H460 M2XRcmZ2dmO2aX;uJGF{e2G7 NFO2V3ExNjFvM{Cg{txO MWe0PEBp MUfpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MY[yOlUyOzF5Mh?=
HKESC-2 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7yNlDDqM7:TR?= MmnWOFjDqGkEoB?= MV\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> MUeyOlQ4PDZ7Mx?=
CaES-17 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLRXo4zOMLizszN MmHDOFjDqGkEoB?= MmTqd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJGlEPTEEoI\hcJVmeyCxZjDvfIFtcXCuYYTpcuKh NX7sT2tCOjZ2N{S2PVM>
HKESC-2 NInOUmtCeG:ydH;zbZMhSXO|YYm= M2HzWlIxyqEQvF2= M2rifFQ5yqCqwrC= NH61XJZz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NV3nO2x7OjZ2N{S2PVM>
CaES-17 NX;INGtZSXCxcITvd4l{KEG|c3H5 NYTNNYk1OjEEoN88US=> NYfHbo8yPDkEoHlCpC=> NWDPOI9xemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>? NFviZoYzPjR5NE[5Ny=>
A549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS1MVE3OCEQvF2= MWS0POKhcMLi NX3PSW1STE2VTx?= Mk[yTWM2OD1zNkOuOEDPxE1? NWXESmVYOjZ2NkS2OFM>
HCC827 NEXicJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrWW2Q2NTF4MDFOwG0> M3r5UFQ5yqCqwrC= NG\kfI5FVVOR NFfIN5hKSzVyPU[5MlIh|ryP MlvqNlY1PjR4NEO=
A549 NYX4dXFJSXCxcITvd4l{KEG|c3H5 MlHGPFAhyrWP NIiwRXo1QMLiaNMg NHPMeVFFVVOR NFyzRXhqdmS3Y3XzJIFxd3C2b4Ppdy=> M4e4fVI3PDZ2NkSz
HCC827 MYPBdI9xfG:|aYOgRZN{[Xl? M{POSlgxKML3TR?= M4HBW|Q5yqCqwrC= MULEUXNQ NIDuZXFqdmS3Y3XzJIFxd3C2b4Ppdy=> M1XGN|I3PDZ2NkSz
SGC-7901/DDP MnfYSpVv[3Srb36gRZN{[Xl? NHLWfoYyOMLiwsXN Mly4NlQhcA>? NED2bVZqdmirYnn0d{BkgWOub3;4fYdmdmG|ZT2yJIFv\CCSLXfsfYNweHKxdHXpckBmgHC{ZYPzbY9v NY\QblVIOjZ2MEe2OVM>
SGC-7901  NIXKVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvOTFRLOjUEoHlCpC=> NVz3PIhSUUN3ME2xNVUvODhizszN MV[yOlQxPzZ3Mx?=
SGC-7901/DDP NUnRbIVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfFenUzPMLiaNMg M4Hy[mlEPTB;M{WuOFUh|ryP Mmr5NlY1ODd4NUO=
SGC-7901/DDP MX7BdI9xfG:|aYOgRZN{[Xl? NGjw[lgyOMLiwsXN NE\QRW8zPCCq M{nHdolv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> NUe3W4xPOjZ2MEe2OVM>
SGC-7901/DDP NFfrOphHfW6ldHnvckBCe3OjeR?= NWPKN2NwOTEEoNM1US=> MX6yOEBp MW\pcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDQMYdtgWOxcILveIVqdiC2aILveYdpKGKub3PrbY5oKEWSMjygZY5lKGmwYXP0bZZifGmwZzDQT2Eh[W6mIFPSSWLDqA>? M4rBeFI3PDB5NkWz
SGC-7901/DDP MnK3SpVv[3Srb36gRZN{[Xl? NXjTbHlQOTEEoNM1US=> MnThNlQhcA>? NYLmTWpE[2G3c3XzJIEhdWG{a3XkJIRm[3KnYYPlJIlvKHSqZTDs[ZZmdCCxZjDCZ4wuOiCycn;0[Ylv NH\qcW4zPjRyN{[1Ny=>
H357 NVjBPJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrER5k4NjVxMUCg{txO MY[0PEBp NWO1PJJPTE2VTx?= NWTpWWFQcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? M33QdVI3ODB7OEe0
TAF MonCSpVv[3Srb36gRZN{[Xl? M4HmfFExyqEEtV2= MmfPO{Bl M3\qUIFn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW| NHLrUIszPTl6N{GyOy=>
TAF MV7GeY5kfGmxbjDBd5NigQ>? MWexNOKhyrWP Ml7sN|AuOTJyIH3pci=> M{TJepBwd3KueTDh[oZm[3S|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=> NXTtbnBkOjV7OEexNlc>
TAF M4TSeWZ2dmO2aX;uJGF{e2G7 MlnmNVDDqML3TR?= NWX2Wo5sPDhiaB?= NUj4T2d6cW6lcnXhd4V{KEWJRmKgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NUGyN4dZOjV7OEexNlc>
PANC-1 NHPsdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PsdFIxNzZyL{GwNEDPxE1? MUeyOE81QC95MjDo M{\UR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NVW5c4xKOjV7N{OwOlI>
PANC-1 MlHwSpVv[3Srb36gRZN{[Xl? MnzVNlAwPjBxMUCwJO69VQ>? NIHGdmwzPCCq MYXheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> NHjh[ZEzPTl5M{C2Ni=>
HeLa  M3jxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWyNOKh|ryPwrC= NVLzVnpTOjUEoHi= NGnYO4FmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= MWKyOVc4ODR{Mx?=
SACC-83 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpfJAzOMLizszNxsA> NVTU[JN1OjUEoHi= NFHQR|ZmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= MXGyOVc4ODR{Mx?=
HeLa  MUHBdI9xfG:|aYOgRZN{[Xl? MkXuNlDDqM7:TdMg MlrCNlTDqGh? MVTlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz NEiyUYszPTd5MESyNy=>
SACC-83 NHP0TmlCeG:ydH;zbZMhSXO|YYm= MU[yNOKh|ryPwrC= MkXiNlTDqGh? NHzHNohmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ M2jOO|I2PzdyNEKz
HeLa  MlHCSpVv[3Srb36gRZN{[Xl? MVSyNE81OC96MDFOwG0> NIX0bo0zPMLiaB?= MoP3eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q> M3zTW|I2PzdyNEKz
SACC-83 NUThOGx[TnWwY4Tpc44hSXO|YYm= M4LFVlIxNzRyL{iwJO69VQ>? NIPLPIgzPMLiaB?= M1:ydJVxemWpdXzheJMhWFSHTjDwZZJ1cWGubImgZpkhcW6qaXLpeIlv\yCVcEGsJIFv\CCjY4TpeoF1\XNiUGTFUkBidmRiaX7hZ5RqfmG2ZYOgRWtV NG\J[3QzPTd5MESyNy=>
HLCZ01 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3naVVDjiJN4MNMgxtVO M2fNb|Q5KGh? M4XuTmROW09? NXHtN3VjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NY\2WpRFOjV5MkS4PVk>
HLCZ01 NHr1VWNHfW6ldHnvckBCe3OjeR?= M4LyXVQxyqEQvF2= NV6xemVROjRiaB?= NI\oTHJFVVOR M322O4lv[3KnYYPld{Bi[2O3bYXsZZRqd25ib3[gS|AwTzFvcHjhd4Uh[2WubIOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MkTPNlU4OjR6OUm=
HLCZ01 NYG0[FNoSXCxcITvd4l{KEG|c3H5 MUe0NOKh|ryP NGLEU2EzPCCq MkfsSG1UVw>? MWTlcohidmOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCLRl6t{tE> MkKzNlU4OjR6OUm=
HLCZ01 NYXvWVc1TnWwY4Tpc44hSXO|YYm= NY\OcmxbPDEEoN88US=> MlrINlQhcA>? MUPEUXNQ NWD2ZnpVcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y NXnoZpJyOjV5MkS4PVk>
MGC803 M{PCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzmNE03OCEQvF2= MkTnO|IhcA>? M2jjNGlEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN NFjQNlkzPTdyMUO3PC=>
SGC7901 M4LWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[3TngxNTZyIN88US=> M1\qTlczKGh? MkDTTWM2OD12Mz61N-KBkcLz4pEJOU4yOiEQvF2= M1nqSFI2PzBzM{e4
MGC803 M1zKS2Z2dmO2aX;uJGF{e2G7 NHqxU3I1OMLizszN MkjHPE8yPi9{NDDo NYDPUnhofXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NYfOVo0zOjV5MEGzO|g>
SGC7901 MnT6SpVv[3Srb36gRZN{[Xl? NGm0dlI1OMLizszN NEf1[mE5NzF4L{K0JIg> NFy5TlR2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> MmTNNlU4ODF|N{i=
MCF-7  NEnFZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXxPFcyNzFyIN88US=> NHnaeJc4OiCq M2HBd2ROW09? MVflcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>? NETLOJkzPTZ4N{WxNC=>
MDA-MB-231  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm0fXUyNzFyIN88US=> MlG0O|IhcA>? MWnEUXNQ M4DlW4VvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w NUjMfFZyOjV4Nke1NVA>
MDA-MB-231 M3T5emZ2dmO2aX;uJGF{e2G7 NUnDS3dPOC12MDFCuW0> MYW0MVI1KGh? Mn7SbY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NWDhNoQxOjV3OEezNlk>
MCF-7 NFyy[m9HfW6ldHnvckBCe3OjeR?= NHTY[WIxNTRyINM1US=> MWW0MVI1KGh? NHTBdVJmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MXeyOVU5PzN{OR?=
MCF7-MX  NXjJTnJQTnWwY4Tpc44hSXO|YYm= M{K0S|AuPDBiwsXN M{nCcFQuOjRiaB?= M3Pnb4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? MlTWNlU2QDd|Mkm=
MDA-MB-231 MXnGeY5kfGmxbjDBd5NigQ>? MkPCNE01OCEEtV2= MXS0MVI1KGh? M{W0[JN1cW23bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhSUKFR{KgeZAhfG9iND6yO{B1cW2nczD0c{Bkd262cn;sJIxmfmWuIHL5JFEzKGkEoB?= NVzGRnd3OjV3OEezNlk>
A2780 MWjGeY5kfGmxbjDBd5NigQ>? NEfLbJA2NzFyL{G1JO69VQ>? NEnCbYU1QCCq Mofj[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnfDNlU1OjR6OUi=
SKOV3  MWXGeY5kfGmxbjDBd5NigQ>? MXy1M|ExNzF3IN88US=> NG\kOJM1QCCq NWnlNlFw\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MojLNlU1OjR6OUi=
A2780 MXfGeY5kfGmxbjDBd5NigQ>? MoPPOU8yOC9zNTFOwG0> MnzyOFghcA>? NHvoW2RmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw M3\ET|I2PDJ2OEm4
SKOV3  M{fkcWZ2dmO2aX;uJGF{e2G7 NXr3R|RsPS9zMD:xOUDPxE1? NF;6ZoE1QCCq M4XnS4Vt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? NH3LTGMzPTR{NEi5PC=>
A2780 NXTwOopwTnWwY4Tpc44hSXO|YYm= NVqzS2xXPS9zMD:xOUDPxE1? M2DiNVQ5KGh? MV3k[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? NXr5PYY1OjV2MkS4PVg>
SKOV3  NWHZ[GEyTnWwY4Tpc44hSXO|YYm= NV;INphYPS9zMD:xOUDPxE1? MW[0PEBp NEHDbnFl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= MmDmNlU1OjR6OUi=
A2780 NHrkVWJHfW6ldHnvckBCe3OjeR?= NXfJRZhPPS9zMD:xOUDPxE1? MWOxJIg> NFG3eY1qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFG5VHAzPTR{NEi5PC=>
SKOV3  MlTvSpVv[3Srb36gRZN{[Xl? NXvBbIt{PS9zMD:xOUDPxE1? NVe0NGJHOSCq NI\l[lhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkjGNlU1OjR6OUi=
HCT-15 NGC1VWJHfW6ldHnvckBCe3OjeR?= NYnnOml4OTBvNUCg{txO M17DNVYuOzZiaB?= MWLpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NFf0fFAzPTJzOECyPC=>
HT-29  MXHGeY5kfGmxbjDBd5NigQ>? M1m1bFExNTVyIN88US=> M1TUZVYuOzZiaB?= MVHpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NWPLfos3OjV{MUiwNlg>
HSC3  MorCR4VtdCCYaXHibYxqfHliQYPzZZk> NG\H[I4x6oDVNECg{txO M1izUVQ5KGh? MXjJR|UxRTJ3LkZCtVEvPzhyIN88US=> MlfFNlUyQTh5OEm=
HSC3  M1ns[2Fxd3C2b4Ppd{BCe3OjeR?= MUKyOUDPxE1? NGS4PFE1QCCq MY\pcoR2[2W|IHHwc5B1d3Orcx?= MlXINlUyQTh5OEm=
HSC3  M4LaXmZ2dmO2aX;uJGF{e2G7 NGHpcIEzPSEQvF2= MUm0PEBp NWTSeJJN\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?= M2PubFI2OTl6N{i5
HSC3  NV6yO3h5TnWwY4Tpc44hSXO|YYm= MU[yOUDPxE1? M2DTOVQ5KGh? NFzmcmNqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> MYWyOVE6QDd6OR?=
HSC3  M4i1dWZ2dmO2aX;uJGF{e2G7 NGKzeJkzPSEQvF2= NEjLd3g4OiCq Mke4[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg MmfENlUyQTh5OEm=
201T  MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHmVmpIPzJiaB?= NGT0cG5FVVOR M2DPcWlEPTB;NEiuOkDDvU1? M4Dk[VI2ODV5OUSx
273T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0eXk3PzJiaB?= M3rwbGROW09? M3i3fmlEPTB;OECuOUDDvU1? NHXhcHYzPTB3N{m0NS=>
Hep-2 NHLrOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\JWYZ1OzBxNUCvNVAxKM7:TR?= MX[xNk8zPC9|Nj:0PEBp NG[2S5RFVVOR NWXNeINZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MoDCNlQ6QTh3NkS=
Hep-2 MV3BdI9xfG:|aYOgRZN{[Xl? NXzqdGxwPTBizszN NFL4OXcxNTR6IHi= NYjBO|BmTE2VTx?= M1zvVYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy MYeyOFk6QDV4NB?=
Hep-2 MXzGeY5kfGmxbjDBd5NigQ>? NHzu[5c2OCEQvF2= M4HBOlAuPDhiaB?= NUL0RnhYTE2VTx?= NVi5fZpCemWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= Mn;UNlQ6QTh3NkS=
Hep-2 NE\md5dHfW6ldHnvckBCe3OjeR?= NYTjT4RQPTBizszN M1\lSVAuPDhiaB?= Mlm3SG1UVw>? NYjWfJFt\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gbHRGWlR? MlrVNlQ6QTh3NkS=
SGC-7901 NWLFRodyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqxNE82OC9zMECg{txO NWDz[GVzOjRxNEivO|IhcA>? MoTsSG1UVw>? Ml3vbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MU[yOFk6Ojl3OB?=
MKN-45 NF:2RXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPlXJcyOC93MD:xNFAh|ryP M4rtdFI1NzR6L{eyJIg> MWnEUXNQ MVvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3jMV|I1QTl{OUW4
SGC-7901 MnLJSpVv[3Srb36gRZN{[Xl? MXixNE82OC9zMECg{txO M4DyR|Q5KGh? NFf5WmpFVVOR NHHDNZBld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M{CzXFI1QTl{OUW4
MKN-45 MkLLSpVv[3Srb36gRZN{[Xl? NIrqNmIyOC93MD:xNFAh|ryP M3fKeFQ5KGh? NGjnenRFVVOR M3\5cYRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWjqVHpmOjR7OUK5OVg>
C666-1 NELqO4ZEgXSxdH;4bYNqfHliQYPzZZk> MViyNE05OCEQvF2= NF7DcnYzPCCq NVnMRXk4\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? M2TYN|I1QDV2OEO4
CNE-1 NVS4co1GS3m2b4TvfIlkcXS7IFHzd4F6 MknpNlAuQDBizszN MVSyOEBp M4rpfIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M1P6SFI1QDV2OEO4
CNE-2 MlztR5l1d3SxeHnjbZR6KEG|c3H5 NFrMeWEzOC16MDFOwG0> MoXCNlQhcA>? MWnk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MViyOFg2PDh|OB?=
C666-1 NGfXe|dEgXSxdH;4bYNqfHliQYPzZZk> MYS2NEDPxE1? MnjmO{Bl NV7Td3k5\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> Mn\pNlQ5PTR6M{i=
CNE-1 NHfmOpFEgXSxdH;4bYNqfHliQYPzZZk> Ml7VOlAh|ryP M1m5VVch\A>? NWPZR|B3\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> MVyyOFg2PDh|OB?=
SNU-1041 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vOZlAuPDBizszN NVe1UFlZPDhiaB?= MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3zRXVI1Pjl{N{Cz
SNU-1041 MoXxSpVv[3Srb36gRZN{[Xl? NXLMSXFFOjBxM{Cg{txO NUnDcpBvPCCq NEPLXoZqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? M1XTPFI1Pjl{N{Cz
SNU-1041 MX7GeY5kfGmxbjDBd5NigQ>? Mo\QNE01OCEQvF2= NYDRUHBiPCCq MWP1dE1z\We3bHH0[ZMhS0iRUNMgZYZ1\XJidILlZZRu\W62IIfpeIghcGmpaDDjc45k\W62cnH0bY9vew>? MnjuNlQ3QTJ5MEO=
SGC-7901 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXnfWhnPTBvMUK1JO69VQ>? NGP0fXMzPC92OD:3NkBp MkPrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHP1W3ozPDZ5NkO5OC=>
SGC-7901 MYDBdI9xfG:|aYOgRZN{[Xl? NHvHSJoyODBizszN M3LF[VczKGh? MYfpcoR2[2W|IHHwc5B1d3Orcx?= MVuyOFY4PjN7NB?=
SGC-7901 MojsSpVv[3Srb36gRZN{[Xl? NEX1VHo4PS9zMECvNVI2KM7:TR?= M1vyWVI1NzR6L{eyJIg> MXPpcoNz\WG|ZYOgZ4F{eGG|ZT24JIFv\CBvOTDtVm5CKGW6cILld5Nqd25iaX6gZo91cCC2aX3lJIFv\CCmb4PlJI1idm6nch?= Ml6zNlQ3PzZ|OUS=
LMeC  MXLGeY5kfGmxbjDBd5NigQ>? MlHzNlAwPTBizszN Mn\zOFghcA>? NI\ZNYxl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= NYnpVYkzOjR4NU[3OFY>
CMeC-1 NF\0ZmdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MY[yNE82OCEQvF2= M2HvR|Q5KGh? Ml\ZbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NUfoN2F2OjR4NU[3OFY>
LMeC M1iyU2NmdGxiVnnhZoltcXS7IFHzd4F6 NInqN|MzOC93MDFOwG0> M1:zdVQ5KGh? NWLHNmlvcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MonPNlQ3PTZ5NE[=
CMeC-1 Ml\KSpVv[3Srb36gRZN{[Xl? Mo\qNlAwPTBizszN MWW0PEBp MVfpcoR2[2W|IFexMXMh[XK{ZYP0 MlTONlQ3PTZ5NE[=
LMeC MlLISpVv[3Srb36gRZN{[Xl? NVzJWWdWOjBxNUCg{txO M4HNV|Q5KGh? NWjifmlDcW6mdXPld{BIOS2VIHHydoV{fA>? M2XrcFI1PjV4N{S2
CMeC-1 NV;2WHBbTnWwY4Tpc44hSXO|YYm= NVjWeWxOOjBxNUCg{txO M{DycVQ5KGh? NVXPVIdH\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXLaOmNJOjR4NU[3OFY>
LMeC MWDGeY5kfGmxbjDBd5NigQ>? MWSyNE82OCEQvF2= NHvXems1QCCq M4HPXIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3\ORVI1PjV4N{S2
CMeC-1 M3;2c2Z2dmO2aX;uJGF{e2G7 NFfzfXgzOC93MDFOwG0> M{S5NlQ5KGh? MUnpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u MYOyOFY2Pjd2Nh?=
LMeC MkHYSpVv[3Srb36gRZN{[Xl? NVfpcWI5OjBxNUCg{txO NF[y[Wg1QCCq NVr2UXM4cW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? MmjZNlQ3PTZ5NE[=
OVCAR-3 M3G1eGNmdGxiVnnhZoltcXS7IFHzd4F6 NGroXJkyOCEEtV2= M33FRVEhcA>? MnnO[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> MWeyOFUzODJ{Nx?=
OVCAR-3 NYflfHpRSXCxcITvd4l{KEG|c3H5 NYHmcFlIOTBiwsXN NHfLZ4cyKGh? NGDUNJpxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB? M2nyc|I1PTJyMkK3
OVCAR-3 MXPGeY5kfGmxbjDBd5NigQ>? NHHGfI0yOCEEtV2= NFHKOYcyKGh? NF3SZnVmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=> NWj2RZdbOjR3MkCyNlc>
OVCAR-3 NF7DdFBHfW6ldHnvckBCe3OjeR?= M{H1e|ExKML3TR?= MWOxJIg> M2LWcYRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> M1vtTFI1PTJyMkK3
OVCAR-3 MontSpVv[3Srb36gRZN{[Xl? M1zOWFExKML3TR?= M{XrdVEhcA>? MX7pcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> MYKyOFUzODJ{Nx?=
CF33 MmLLSpVv[3Srb36gRZN{[Xl? MljmNVAxKM7:TR?= MWOyOEBp MVjpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIFPPXE0zKHC{b4TlbY4h\XiycnXzd4lwdg>? MlrTNlQ2ODN5OEK=
CF33 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLnNVAuOTByIN88US=> MWGwMVQh\A>? NUS1V5BycW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3rqZVI1PTB|N{iy
CF33 MY\GeY5kfGmxbjDBd5NigQ>? NIHzN5IyOC1zMECg{txO NGLRb3Y1NTJ2IHi= NYTvUmJs\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 MWCyOFUxOzd6Mh?=
LNCaP NGX5PI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULUd49XOi93L{GwJO69VQ>? NX7NOZl{QTZiaB?= NHu1OVdqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu NFO5fmIzPDJ7Nkm3PC=>
LNCaP NGfleHFCeG:ydH;zbZMhSXO|YYm= M4L6eVIwPS9zMDFOwG0> NUmyO5NPQTZiaB?= NHj0em9qdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MX6yOFI6Pjl5OB?=
PC-3  NXLKfnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWwMVUxKM7:TR?= NUXY[3dYPDkkgJno MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MWCyOFEzPzh6Mh?=
PC-3  M3fRdmNmdGxiVnnhZoltcXS7IFHzd4F6 NUi1ZnlNOC1zMECg{txO MlHpO|IhcA>? M3rxZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4f2NlI1OTJ5OEiy

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Water Insoluble
Ethanol '33 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635
Smiles CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04526197 Enrolling by invitation Drug: ALXN1840|Drug: Celecoxib Wilson Disease Alexion Pharmaceuticals July 8 2020 Phase 1
NCT04447261 Recruiting Drug: BI 1356225|Drug: Placebo Obesity Boehringer Ingelheim June 30 2020 Phase 1
NCT03896113 Recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain November 13 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID